Genetic variants in human carbonyl reductase 3 (CBR3) and their influence on doxorubicin pharmacokinetics in Asian breast cancer patients

被引：0
|
作者：
Fan, L.
Guo, J. Y.
Wong, C. I.
Lim, R.
Yap, H. L.
Khoo, Y. M.
Iau, P.
Goh, B. C.
Lee, H. S.
Lee, S. C.
机构：
[1] Natl Univ Singapore, Singapore, Singapore
[2] Natl Univ Singapore Hosp, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2505
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients
    Lal, Suman
    Sandanaraj, Edwin
    Wong, Zee Wan
    Ang, Peter C. S.
    Wong, Nan Soon
    Lee, Edmund J. D.
    Chowbay, Balram
    CANCER SCIENCE, 2008, 99 (10) : 2045 - 2054
  • [2] Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity
    Fan, Lu
    Goh, Boon-Cher
    Wong, Chiung-Ing
    Sukri, Norita
    Lim, Siew-Eng
    Tan, Sing-Huang
    Guo, Jia-Yi
    Lim, Robert
    Yan, Hui-Ling
    Khoo, Yok-Moi
    Lau, Philip
    Lee, How-Sung
    Lee, Soo-Chin
    PHARMACOGENETICS AND GENOMICS, 2008, 18 (07): : 621 - 629
  • [3] Identification of the Promoter of Human Carbonyl Reductase 3 (CBR3) and Impact of Common Promoter Polymorphisms on Hepatic CBR3 mRNA Expression
    Jianping Zhang
    Javier G. Blanco
    Pharmaceutical Research, 2009, 26 : 2209 - 2215
  • [4] Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3)
    Lakhman, SS
    Ghosh, D
    Blanco, JG
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (02) : 254 - 257
  • [5] Identification of the Promoter of Human Carbonyl Reductase 3 (CBR3) and Impact of Common Promoter Polymorphisms on Hepatic CBR3 mRNA Expression
    Zhang, Jianping
    Blanco, Javier G.
    PHARMACEUTICAL RESEARCH, 2009, 26 (09) : 2209 - 2215
  • [6] Characterization of the human carbonyl reductase 3 (CBR3) by site-directed mutagenesis
    El-Hawari, Y.
    Pilka, E.
    Martin, H. -J
    Oppermann, U.
    Maser, E.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2008, 377 : 67 - 67
  • [7] CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin
    Lang, Jennifer K.
    Karthikeyan, Badri
    Quinones-Lombrana, Adolfo
    Blair, Rachael Hageman
    Early, Amy P.
    Levine, Ellis G.
    Sharma, Umesh C.
    Blanco, Javier G.
    O'Connor, Tracey
    CARDIO-ONCOLOGY, 2021, 7 (01)
  • [8] CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin
    Jennifer K. Lang
    Badri Karthikeyan
    Adolfo Quiñones-Lombraña
    Rachael Hageman Blair
    Amy P. Early
    Ellis G. Levine
    Umesh C. Sharma
    Javier G. Blanco
    Tracey O’Connor
    Cardio-Oncology, 7
  • [9] Mapping of a novel human carbonyl reductase, CBR3, and ribosomal pseudogenes to human chromosome 21q22.2
    Watanabe, K
    Sugawara, C
    Ono, A
    Fukuzumi, Y
    Itakura, S
    Yamazaki, M
    Tashiro, H
    Osoegawa, K
    Soeda, E
    Nomura, T
    GENOMICS, 1998, 52 (01) : 95 - 100
  • [10] Carbonyl reductase 1 polymorphisms: Influence of diplotype structures on doxorubicin disposition in Asian breast cancer patients
    Lal, S.
    Sandanaraj, E.
    Xiang, X. Q.
    Wong, Z. W.
    Peter, C. S. Ang
    Wong, N. S.
    Lee, E. J.
    Chowbay, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345